RetinaCME
ARTICLECME

RetinaCME® Presents: Intravitreal Interventions: Volume 6, Number 1

Author(s)/Faculty: Michael S. Ip, MD; Jennifer I. Lim, MD; Andrew A. Moshfeghi, MD, MBA; Ehsan Rahimy, MD; Carl D. Regillo, MD, FACS
Release Date: 6/30/2017Expiration Date: 6/29/2018
Credit Type: CMENumber of Credits: 1.25
Content Type: ArticleProvider:
Intravitreal drug delivery of agents, such as anti-VEGF therapies and corticosteroids, has rapidly become standard therapy in retinal vascular diseases. With the continued refinement of dosing schedules, as well as ongoing assessment of current and emerging therapies, there is the potential to further improve patient outcomes. Within this series, the latest clinical data and updated guidelines will be reviewed providing guidance for the optimal treatment of several retinal vascular diseases, including diabetic retinopathy, diabetic macular edema, age-related macular degeneration, and retinal vein occlusion.